

## **Cytokine and CAM Antagonists: S1-P Receptor Modulators**

Please fax this completed form to (833) 645-2734 OR mail to: Centene Pharmacy Services | 5 River Park Place East, Suite 210 | Fresno, CA 93720. You can also complete online at <a href="CoverMyMeds.com">CoverMyMeds.com</a>.

Coordinated Care of Washington, Inc. (Apple Health) Preferred Drug list: <a href="https://www.coordinatedcarehealth.com/content/dam/centene-pharmacy/pdl/FORMULARY-CoordinatedCare">https://www.coordinatedcarehealth.com/content/dam/centene-pharmacy/pdl/FORMULARY-CoordinatedCare Washington.pdf</a>

For policy criteria, see: <a href="https://www.coordinatedcarehealth.com/content/coordinatedcare/en">https://www.coordinatedcarehealth.com/content/coordinatedcare/en</a> us/providers/resources/clinical-payment-policies.html/

Date of request:	Reference #:		MAS:					
Patient Date of birth		ProviderOn		e ID or Coordinated Care ID				
Pharmacy name	Pharmacy NPI Teleph		one number Fax number					
•	,							
Prescriber	Prescriber NPI	Teleph	one number	Fax number				
Medication and strength		Dire	ections for use	<u> </u>	Qty/Days supply			
<ol> <li>Is this request for a continuation of therapy?  Yes  No         If yes, does patient have clinical documentation demonstrating disease stability or a positive clinical response?  Yes  No</li> <li>Is this prescribed by, or in consultation with, any of the following? Check all that apply:  Gastroenterologist  Neurologist  Other. Specify:</li> </ol>								
3. What is patient current v	3. What is patient current weight:kg Date taken:							
<ul> <li>4. Indicate patient's diagnosis and answer the associated questions as indicated:</li> <li>Multiple Sclerosis (questions 5 - 10)</li> <li>Ulcerative Colitis (questions 11 – 15)</li> </ul>								
For diagnosis of Multiple Sclerosis								
<ul> <li>Has patient had treatment with one or more preferred Multiple Sclerosis medications on the Apple Health Preferred Drug List (AHPDL) that was ineffective, contraindicated or not tolerated?</li> <li>Yes. List each medication and duration of trial:</li> </ul>								
Medication Name:				Duration: _				
Medication Name:			Duration:					
Medication Name:	Medication Name:				Duration:			
No. Explain why a pr	referred product(s) have	not bee	n tried:					
6. Will the requested medi sclerosis?	cation be used in combir	nation w	ith other dis	ease modifying	g therapies (DMTs) for multipl			

7.	Does patient have diagnosis  Relapsing remitting disea Clinically isolated syndro	ise (RRMS) Act		pply: y progressive disease (SPMS)				
8.	Has diagnosis been confirmed and documented by a laboratory report (e.g. MRI)?   Yes   No							
9.	Have baseline assessments of any of the following been submitted? Check all that apply:  Number of relapses per year Expanded disability status scale (EDSS score)							
10.	D. For continuation of therapy: Has documentation been submitted demonstrating disease stability or a positive clinical response (i.e., decrease in number of relapses per year, improvement in EDSS score)?							
For dia	gnosis of Ulcerative Colitis							
11.	Will the requested medication	on be used in combination v	with another	Cytokine and CAM medication?				
12.	<ul><li>12. Has patient had treatment with one or more preferred Cytokine and CAM medications on the Apple Health Preferred Drug List (AHPDL) that was ineffective, contraindicated or not tolerated?</li><li>Yes. List each medication and duration of trial:</li></ul>							
	Medication Name:			Duration:				
	Medication Name:			Duration:				
	Medication Name:			Duration:				
	No. Explain why a prefer	red product(s) have not be	en tried:					
13.	13. Have baseline assessments been submitted (e.g., stool frequency, endoscopy results, presence of rectal bleeding, disease activity scoring tool)?   Yes No							
14.	<ul> <li>14. Has treatment with conventional therapy (e.g., systemic corticosteroids, azathioprine, mesalamine, sulfasalazine) been ineffective, unless all are contraindicated, or not tolerated [minimum trial of 12 weeks]?</li> <li>Yes</li> <li>No</li> </ul>							
15.	clinical response (e.g., decre	ased stool frequency, decre	eased rectal b	emonstrating disease stability or a positive bleeding, improvement in endoscopic activity, nt on a disease activity scoring tool)?				
CHART NOTES ARE REQUIRED WITH THIS REQUEST								
			T					
Prescrib	er signature	Prescriber specialty		Date				

Centene Pharmacy Services will respond via fax or phone within 24 hours of receipt of the request. Requests for prior authorization must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)